MedDataX Logo

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

NCT ID: NCT01308606

Last Updated: 2012-10-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare absorption of TMC435 formulated as 2 different types of capsules. After that, the absorption of one chosen TMC435 capsule will be compared when taken under fasting conditions or together with a standard or a high-fat meal. This will be done in healthy volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label, randomized, single-dose, crossover trial in healthy volunteers. Crossover means that participants may receive different interventions sequentially during the trial. Randomized means that you will be assigned to a treatment sequence by chance, like flipping a coin. Open-label means that you and your physician will know what treatment you will receive. The study will consist of 3 phases: a screening phase, a treatment phase and a follow-up phase. Total study duration for an individual participant will be up to 6 or 7 weeks. Once found eligible after the screening phase, participants will take part in one of the two parts of the treatment phase. In the first part, a group of 24 participants will receive two treatment sessions, A and B. The order in which the treatments are given will be determined by chance. Treatment A is a single dose of TMC345 as one formulation (1 capsule). Treatment B is a single dose of TMC435 as another formulation (1 other type of capsule). Both treatments will be taken without food. In between the 2 sessions, there will be at least 7 days. In the second part, another group of 24 participants will receive 3 treatment sessions, C, D, and E. The order in which these treatments are given will be determined by chance. All 3 treatments will consist of a single dose of TMC435 as one of the 2 formulations given in the first part. In Treatment C this will be given without food, in Treatment D with a standardized breakfast and in Treatment E with a high-fat breakfast. In between the sessions, there will be at least 7 days. For all treatment sessions, participants will enter the study center the day before dosing and will remain there until the evening of the day after. The 3 following mornings, participants will come back to the study center. Five to 7 days after dosing, participants will have a last follow-up visit at the study center (follow-up phase). During the study, safety will be monitored, and during the treatment phase, at specified timepoints, blood samples will be taken for pharmacokinetic evalutions (effect of the body on the drug). In every treatment session, a single oral 150 mg TMC435 capsule will be given. One formulation will be a gelatin capsule. The other formulation will be a hydroxypropylmethylcellulose (HPMC) capsule.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

TMC435-TiDP16-C116 TMC435-C116 TMC435 HCV Hepatitis C Hep C healthy volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

001

TMC435 gelatin capsule Single intake of one 150-mg capsule without food

Group Type EXPERIMENTAL

TMC435 gelatin capsule

Intervention Type DRUG

Single intake of one 150-mg capsule without food

002

TMC435 HPMC capsule Single intake of one 150-mg capsule without food

Group Type EXPERIMENTAL

TMC435 HPMC capsule

Intervention Type DRUG

Single intake of one 150-mg capsule without food

003

TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food

Group Type EXPERIMENTAL

TMC435 HPMC or gelatin capsule

Intervention Type DRUG

Single intake of one 150-mg capsule without food

004

TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast

Group Type EXPERIMENTAL

TMC435 HPMC or gelatin capsule

Intervention Type DRUG

Single intake of one 150-mg capsule after standardized breakfast

005

TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast

Group Type EXPERIMENTAL

TMC435 HPMC or gelatin capsule

Intervention Type DRUG

Single intake of one 150-mg capsule after high-fat breakfast

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TMC435 HPMC capsule

Single intake of one 150-mg capsule without food

Intervention Type DRUG

TMC435 HPMC or gelatin capsule

Single intake of one 150-mg capsule after high-fat breakfast

Intervention Type DRUG

TMC435 HPMC or gelatin capsule

Single intake of one 150-mg capsule without food

Intervention Type DRUG

TMC435 HPMC or gelatin capsule

Single intake of one 150-mg capsule after standardized breakfast

Intervention Type DRUG

TMC435 gelatin capsule

Single intake of one 150-mg capsule without food

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-smokers for at least 3 months prior to screening
* Have a body mass index of 18.0 to 30.0 kg per square meter
* Be healthy on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening

Exclusion Criteria

* Use of disallowed therapies, including over-the-counter products and dietary supplements
* Having previously participated in a multiple-dose trial or more than 3 single-dose trials with TMC435
* Received an investigational drug or used an investigational medical device within 90 days before the planned start of treatment
* History or evidence of current use of alcohol, barbiturate, amphetamine, recreational, or narcotic drug use
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tibotec Pharmaceuticals, Ireland

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tibotec Pharmaceuticals Clinical Trial

Role: STUDY_DIRECTOR

Tibotec Pharmaceutical Limited

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TMC435-TiDP16-C116

Identifier Type: -

Identifier Source: secondary_id

CR015940

Identifier Type: -

Identifier Source: org_study_id